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Abstract: The first-line therapy for patients with center-involving diabetic macular edema 
(DME) is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or without 
adjunctive macular laser treatment. However, a significant proportion of patients have persistent 
and recurrent edema despite repeated anti-VEGF injections. The fluocinolone acetonide (FA) 
190 μg intravitreal implant has been shown in pivotal clinical trials to be efficacious for the 
treatment of DME and has been approved in many countries for use in patients who have not 
responded to first-line therapy. In this report, we have collated the latest data from the increasing 
number of studies to illustrate the pattern of usage of the Iluvien FA implant for DME during the 
current anti-VEGF era. We have shown that there is now a wealth of published evidence from 
real-world studies to support the clinical utility of the FA implant in achieving further resolution 
of edema and improving visual acuity outcomes in this challenging group of patients.
Keywords: fluocinolone acetonide, Iluvien, diabetic macular edema
Introduction
The first-line therapy for patients with center-involving diabetic macular edema (DME) 
is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or 
without adjunctive macular laser treatment. However, a significant proportion of 
patients have persistent and recurrent edema despite repeated anti-VEGF injections. 
The fluocinolone acetonide (FA) 190 μg intravitreal implant (0.2 μg/day; Iluvien®, 
Alimera Sciences, Inc., Alpharetta, GA, USA) was found to be efficacious for the 
treatment of DME in the landmark, pivotal Fluocinolone Acetonide in Diabetic Macu-
lar Edema (FAME) studies (FAME A and B), which were well-designed, Phase III, 
multicenter, randomized clinical trials designed to assess the efficacy and safety of a 
single injection of the FA implant over a 36-month period versus the standard of care.1,2 
At the time the FAME studies were conducted, the standard of care was mainly laser 
photocoagulation. During the study, 34.8% of the control group received off-protocol 
treatments, such as anti-VEGF agents or intravitreal triamcinolone, compared with 
13.4% in the FA implant-treated group.1 Furthermore, 62.7% (n=235/375) of eyes 
receiving the FA implant were phakic at baseline and 80.0% of eyes receiving the FA 
implant (0.2 μg FA arm) required cataract surgery during the course of the 3-year trial.1 
These two factors have made it difficult for clinicians to translate the evidence from 
the FAME studies directly into their current clinical practice, especially regarding the 
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role of the FA implant among the current armamentarium 
of anti-VEGF agents that are now well established as the 
first-line therapies for DME.3–7 Currently, there have been 
no studies published or planned to compare the head-to-head 
performance of the FA implant and anti-VEGF as first-line 
agents for the therapy of DME.
Recent evidences from follow-up and exploratory analyses 
of data from large-scale clinical trials on ranibizumab and 
aflibercept with or without adjuvant laser treatment have 
shown that a sizeable proportion of patients have persistent 
macular edema, which is unresponsive to anti-VEGF therapy 
either as monotherapy or in combination with prompt or 
delayed or repeated macular grid laser treatment.8–11 One 
report showed that half of the eyes treated for DME with intra-
vitreous ranibizumab have persistent central-involved DME 
up to 24 weeks after initiating treatment.12 A recent analysis 
of Protocol I data showed that ~40% of eyes had suboptimal 
early response (,5-letter improvement in best corrected visual 
acuity [BCVA]) at 12 weeks and the majority had suboptimal 
visual outcomes after 3 years of treatment.13 Given this limita-
tion of anti-VEGF agents, it is fortunate that the FA implant 
has been licensed for the treatment of vision impairment 
associated with chronic DME that is insufficiently responsive 
to available therapies.14,15 This has led to an increasing usage 
of the FA implant for patients with DME who have responded 
suboptimally to therapy, although the definition of insufficient 
response has been quite variable in the published literature.16 
As there have been no prospective studies to evaluate the role 
of the FA implant in the current anti-VEGF era, clinicians have 
to rely on a less robust evidence base and their own clinical 
experience to guide their utilization of the FA implant and 
especially on how to define insufficient response.
In this report, we aim to collate and distil the reports from 
an increasing number of studies, which are largely uncon-
trolled and retrospective, to illustrate the pattern of usage 
of the FA implant for chronic DME during the current anti-
VEGF era and also to summarize their clinical outcomes and 
safety findings. All references to the FA implant used in the 
FAME studies relate to the low-dose and not the high-dose 
implant. Comparison of the FA implant with the dexametha-
sone implant has not been made as this is beyond the scope 
of this review. It is hoped that this summary will be useful 
for clinicians in clinical decision-making and also to enable 
greater confidence in justifying the use of the FA implant 
for chronic DME, especially when anti-VEGF agents have 
been ineffective in resolving the edema and when recurrent 
or persistent edema is causing visual decline or requiring 
very frequent injections.
General mechanisms of action of 
corticosteroids in DMe
The pathogenesis of DME has been the focus of several 
review articles published in recent years. Multiple inflamma-
tory and neurodegenerative pathways have been implicated. 
The major component underlying the development of macular 
edema is believed to be the presence of chronic, low-grade 
inflammation of the retinal microvasculature contributing 
eventually to the breakdown of tight junctions that form 
the blood−retinal barrier, which, in turn, increases retinal 
vascular permeability. Corticosteroids inhibit prostaglandin 
and leukotriene synthesis and interfere with other pathways, 
including intercellular adhesion molecule-1, interleukin-6, 
VEGF-α, and stromal cell-derived factor-1.17–20 Corticos-
teroids also decrease paracellular permeability and increase 
tight junction integrity by directly restoring tight junction 
proteins to their appropriate location at the cell border and 
by increasing the gene expression of those proteins.21,22
Formulation and pharmacokinetics of 
the FA implant
FA has an empirical formula of C
24
H
30
F
2
O
6
 and is a small 
molecule with a molecular weight of 452.49 Da.23 It is 
formulated as a sustained-delivery, low-dose, intravitreal, 
non-bioerodible implant, which consists of a cylindrical 
polyimide tube measuring 3.5 mm in length and 0.37 mm 
in diameter and containing 190 μg of FA as the active 
ingredient. The implant is injected through the pars plana into 
the vitreous cavity using a 25-gauge applicator in the same 
manner as in the intravitreal injection and can be done in the 
office setting.24 After the injection, there is a slow release of 
the drug from one end of the polyimide cylinder. The dose 
of 190 μg releases the drug at a rate of 0.2 μg per day. The 
release kinetics of FA implants have been studied in humans 
and rabbits, and the corticosteroid maximum concentration in 
the aqueous found with FA implants were found to be several 
orders of magnitude lower than either triamcinolone or the 
bioerodible system releasing dexamethasone (Ozurdex®; 
Allergan)25 and also lower than the aqueous maximum 
concentration level of commonly used corticosteroid eye 
drops such as Pred Forte 1% (mean C
max
 between 669.9 and 
1,130 ng/mL vs 2.17 ng/mL for the FA implant).
FAME trial – efficacy
The efficacy of the FA implant was evaluated in the FAME 
trial.1,2 Patients were randomized to either a sham injection 
(n=185), a low-dose (0.2 μg/day; n=375), or a high-dose 
(0.5 μg/day) FA implant (n=393). Patients could receive 
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rescue laser photocoagulation during the study if there was 
persistent macular edema. After 1 year, they could receive a 
second treatment if their vision decreased or foveal thickness 
increased. Clinicians could use off-protocol therapies such as 
intravitreal anti-VEGF injections or intravitreal triamcino-
lone in patients at their discretion and those patients treated 
with off-protocol medications were not withdrawn and where 
possible their actual final outcome measures were analyzed. 
The primary end point was a gain of $15 letters at 24 months 
with follow-up to 36 months.1,2 At month 36, the proportion 
of patients gaining $15 letters was 18.9% in the FA implant 
group versus 21.4% in the sham group (P=0.030). Foveal 
thickening was also markedly reduced in the FA-treated 
group after the first follow-up visit (week 1) and a sustained 
reduction was maintained through to month 36.1,2
FAMe trial – safety
The FAME studies reported that by the end of the 3-year 
follow-up period, phakic patients who received the FA 
implant developed cataracts in 81.7% versus 50.4% in the 
sham group and 80% required cataract surgery versus 27.3% 
in the sham group. This high rate of cataract formation was 
attributed to the effect of FA in the treated group and to the 
off-protocol use of other short-acting steroids such as triam-
cinolone particularly in the control group.1
Cataract formation is a well-known side effect of steroid 
use. While 80% of phakic patients in the FA implant group 
developed cataract, the overall visual benefit after cataract 
surgery was similar to that in pseudophakic patients. This was 
demonstrated in a post hoc analysis of the FAME studies data 
in chronic and non-chronic DME in patients who underwent 
cataract extraction before or after receiving the implant.26 
In this analysis, the BCVA after 36 months was comparable 
in both groups. In addition, most patients who underwent 
cataract surgery experienced a net gain in BCVA from pre-
surgery baseline and from original study baseline. When 
only those patients who had cataract surgery after receiving 
the implant were evaluated, patients with chronic DME were 
numerically more likely to gain a $15-letter improvement 
than those with non-chronic DME (42.3% vs 27.5%). These 
results demonstrated that patients who had cataract surgery 
after receiving the FA implant experienced long-term visual 
gains that were no worse and possibly better than outcomes 
observed in patients who were already pseudophakic when 
they received the FA implant. These results could be attrib-
uted to a possible protective effect of corticosteroid therapy 
from postoperative macular edema when administered prior 
to cataract surgery. These data, therefore, provide some 
evidence for the use of the FA implant in phakic and in 
pseudophakic eyes.26,27
In the FAME studies, raised intraocular pressure (IOP) 
was managed with IOP-lowering drops in 38.4% of patients 
in the FA implant group versus 14.1% in the sham control 
group. In terms of timing of IOP events, the onset of ocular 
hypertension began within 2–4 weeks with a maximum at 
24–48 weeks and a return to baseline at 9–12 months.1,2,28 
In a small number of cases (1.3%), laser trabeculoplasty 
was used to manage raised IOP in the FA-treated group. 
Incisional surgery was also used to manage raised IOP and 
was performed in 4.8% of patients in the FA implant group 
versus 0.5% in the sham group.
In the FAME trial, patients who had prior corticosteroid 
could be enrolled into the study only if they did not have 
an IOP response; that is, they were not steroid responders. 
Given this selection criterion, another post hoc analysis 
on the FAME data set by Parrish et al reported that among 
the 72 patients receiving FA implant, who received prior 
corticosteroid (and therefore would have been non-steroid 
responders), none required IOP-lowering surgery.29 In con-
trast, out of 294 patients who did not have prior intravitreal 
corticosteroid (and therefore had not had their steroid response 
status confirmed), 18 (6.1%) required IOP-lowering surgery 
(P=0.030).29 This highlights the potential value of knowing if 
patients have a strong IOP response to corticosteroid therapy 
and is reflected in the approved US indication of FA implant 
for only those eyes that have not had any clinically significant 
IOP response to prior corticosteroid therapy.24
A recent assessment of the fundus photographs from 
the FAME trial data was conducted to determine whether 
FA-treated patients had any clinically significant glaucoma-
tous changes in the optic nerve head.30 It is noteworthy that 
the use of the FA implant is contraindicated in the presence of 
pre-existing glaucoma.24 The post hoc analysis of the changes 
in the mean cup-to-disc ratio (CDR) by Parrish et al30 showed 
that there was no significant increase in the proportion of 
patients experiencing a CDR increase of .0.2 with the FA 
implant versus the sham control. This finding suggested that 
although IOP increases occur in patients after treatment with 
the FA implant, glaucomatous optic nerve changes were 
similar between FA and non-FA-treated patients within the 
3-year study period. Despite this reassuring report of the 
benefit of the post hoc analysis of CDRs, it is important to 
follow patients with established steroid induced glaucoma 
and disk damage carefully with regular visual field testing 
as perimetry is regarded as more useful than optic disk mor-
phometry in monitoring established glaucoma.31
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Approved indications of FA implant
In Europe, the 0.2 μg/day, FA implant (Iluvien) is approved 
for the treatment of vision impairment associated with 
chronic DME considered insufficiently responsive to avail-
able therapies. In the USA, it is approved for the treatment 
of DME in patients who have been previously treated with a 
course of corticosteroids and did not have a clinically signifi-
cant rise in IOP.24 In the UK, National Institute for Health and 
Care Excellence (NICE) guidance, based on efficacy-to-cost, 
stipulates its use only in pseudophakic eyes with DME that 
has not responded sufficiently to available therapies.15
Real-world outcomes
In recent years, there have been numerous clinical studies 
on the use of the FA implant in those patients whose DME 
has been insufficiently responsive to laser therapy and 
intravitreal anti-VEGF agents. This emerging evidence has 
been vital for clinicians to justify the use of the FA implant 
in those patients who have not responded to the first-line 
therapy of laser and anti-VEGF agents. The study by Massin 
et al was the first real-world study to assess the effective-
ness of the FA implant at the Lariboisière Hospital in Paris, 
France.32 This was a Phase IV, prospective study evaluating 
the efficacy and safety of the FA implant in chronic DME 
patients considered insufficiently responsive to laser only 
(Group 1) or laser and anti-VEGF treatment (Group 2). 
Although only 16 patients (17 eyes) were included in this 
study, they all had chronic and particularly recalcitrant 
DME. Baseline visual acuities and central retinal thick-
nesses (CRT) were 47.7 letters and 550.6 μm (Group 1) and 
44.8 letters and 701 μm (Group 2), respectively. The median 
duration of DME was 7.6 years in Group 1 and 3.6 years 
in Group 2, respectively, and the majority of eyes were 
pseudophakic as .80% of patients in both groups had prior 
intravitreal corticosteroid. Despite the poor visual acuity and 
the chronicity of DME, by month 12, the treated eyes had 
reduction of edema and visual gains of 299 μm and 5.6 letters 
(Group 1) and 251 μm and 0.9 letters (Group 2), respectively. 
The evidence from this study provides some justification 
for using the FA implant in those patients with lower visual 
acuity and chronic and persistent DME, despite prior intra-
vitreal anti-VEGF and prior intravitreal corticosteroid who 
are often encountered in the real-world setting.32–36
A case series of 15 eyes in 10 patients with similar char-
acteristics was published by Schmit-Eilenberger in 2015.33 
Prior to treatment with the FA implant, all had an insufficient 
response to either anti-VEGF and/or triamcinolone or dex-
amethasone implants. Ten eyes were pseudophakic before 
or shortly after receiving the FA implant and seven eyes 
had prior vitrectomy. Follow-up was unfortunately variable 
between two and 36 weeks with a majority of patients with 
at least 20 weeks of follow-up, but nevertheless there was an 
improvement in BCVA in eleven (73.33%) eyes, unchanged 
in two (13.33%) eyes, and decreased in two (13.33%) eyes 
at the last follow-up visit in comparison to baseline. In other 
words, visual acuity improved or was maintained in 86.7% 
of eyes. This case series highlights the types of patients 
who were being selected for treatment with the FA implant. 
Patients were either phakic or pseudophakic, but all had 
chronic DME, which was unresponsive to intravitreal anti-
VEGF and in many cases intravitreal triamcinolone and 
dexamethasone implants as well.
The types of patients that clinicians are selecting for 
treatment with the FA implant in the real world can also be 
seen from the consecutive case series published by Elaraoud 
et al of 22 patients who received an FA implant over an 
8-month period in three hospital sites.34 In this series, due to 
the restriction of its use in the UK to pseudophakic patients 
only, none of the treated eyes were phakic but all eyes had 
received prior intravitreal anti-VEGF therapies including six 
eyes with prior intravitreal triamcinolone. At 3 months after 
treatment with an FA implant, the mean reduction in CRT 
was 148 μm and the mean gain in visual gain was 6.4 letters. 
The majority (68.2%) of patients had improved CRT and 
improved vision at 3 months, but 4 out of the 22 eyes did not 
have any reduction in CRT at this time point.34 In another 
paper, Elaraoud et al also reported 6- and 12-month outcomes 
of a series of patients receiving bilateral FA implants for 
bilateral chronic DME. At 12 months, 9 out of 10 patients 
had sustained and improved VA with a mean improvement in 
visual of acuity of 10.5 letters and a mean reduction in CRT 
of -357.9 μ from baseline.35,36 Another case of a bilateral 
FA implant was reported by Bertelmann and Schulze in a 
31-year-old man with type 1 diabetes who received an FA 
implant in the left eye followed by the right eye 6 months 
later.37 In the left eye, central macular thickness decreased 
from 642 μ to 372 at month 13. BCVA also improved rapidly 
following the FA implant from 0.3 (a Snellen fraction of 
20/60 or a 61 ETDRS letter score) at baseline to 0.5 (20/40 or 
a 70 ETDRS letter score) after 1 month, which was sustained 
through to month 9. Cataract formation resulted in a reduc-
tion of BCVA at month 13, although this improved following 
cataract surgery. The right eye also had resolution of DME 
at 6 months of follow-up. These small case series lend some 
support to the use of FA implants in bilateral cases.
It has been postulated that in vitrectomized eyes, DME 
may be less responsive to anti-VEGF and more responsive to 
slow release formulations such as a dexamethasone implant 
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or an FA implant due to the increased clearance of anti-VEGF 
delivered in a single bolus injection.38–40 Kumar et al reported 
two cases of the FA implant used in refractory DME in vitrec-
tomized eyes, which completely resolved up to 1 year.41 The 
first was a 50-year-old female who received multiple intra-
vitreal anti-VEGF and triamcinolone injections for chronic 
DME and subsequent vitrectomy for severe macular traction. 
After vitrectomy, DME was still present despite additional 
intravitreal therapies. The patient received an FA implant 
7 months after vitrectomy, which then resulted in resolution 
of DME with no further adjunctive therapy up to 1 year. The 
second case was a 48-year-old male who underwent right 
eye vitrectomy 3 years prior to bilateral treatment with an 
FA implant. The right DME resolved gradually over 1 year 
without adjunctive therapy but in the left eye DME responded 
only briefly before recurring. A year later, vitrectomy, with 
the FA implant preserved, was performed which led to DME 
resolution.41 These cases demonstrate the effectiveness of 
the FA implant up to 1 year after initial treatment in vitrec-
tomized eyes and was the first reported case of reduction 
of edema in a vitrectomized eye which had received an FA 
implant before vitrectomy which was done without removal 
of the implant. Efficacy was demonstrated up to 2 years in 
one case report which showed that a single injection of the 
0.2 μg/day FA implant lead to improvements in VA and CFT 
within 7 days. This was maintained over 2 years of follow-up 
despite 11 previous injections of ranibizumab.42
Real-world outcomes of intraocular 
pressure effects of the FA implant
As mentioned earlier, 38.4% of FA-treated patients required 
IOP-lowering medication as opposed to 14.1% in the sham 
group in the FAME trial.1 As definite steroid responders were 
excluded from the FAME trial and the use of IOP-lowering 
drugs was strictly controlled by the study protocol, it is useful 
to review the experiences seen in the real-world studies on 
the IOP effects of the FA implant.
In the study by Elaraoud et al of 22 patients unilater-
ally treated with the FA implant and a 3-month follow-up 
period, there was no substantial increase in IOP. The mean 
baseline IOP was 16.9 mmHg (standard deviation [SD]: ±3.1; 
range: 10–22 mmHg), with the mean change of 0.3 mmHg 
(SD: ±3.1; range: -7 to +5 mmHg) at month 3.34 Four eyes 
were receiving IOP-lowering drops (timolol and/or latano-
prost) prior to the FA implant. Following treatment with 
the FA implant, one additional eye required IOP-lowering 
medication. The case series by Elaraoud et al of 5 bilateral 
FA implants (10 eyes treated) had a 12-month follow-up. 
The mean IOP was 13.7±3.6 mmHg (mean ± SD) at 
baseline; 15.5±4.0 mmHg at 6 months; and 16.0±3.3 mmHg 
at 12 months. In all cases, IOP remained ,22 mmHg.35
Massin et al reported elevated IOP in 3 out of 17 eyes; 
one patient in the prior laser-only group (maximal IOP 
value was 32 mmHg at month 1) and two patients in prior 
laser and $3 monthly anti-VEGF therapy group (25 mmHg at 
month 3 and 28 mmHg at month 12). These three patients had 
their IOP well controlled by IOP-lowering eye drops.32 The 
mean IOP remained stable in both groups from baseline to 
month 12: from 15.3±2.7 (mean ± SD) to 16.8±3.5 mmHg in 
Group 1 and from 15.5±2.5 to 18.2±4.7 mmHg in Group 2.
In Schmit-Eilenberger’s case series of 15 eyes, 3 eyes had 
a rise of IOP of .7 mmHg.33 The rise in IOP was controlled 
either by a sectorial cyclocryotherapy and/or a medical treat-
ment with fixed combinations.
Bertelman and Schulze’s case study showed an increase 
in IOP in the left eye from 20 mmHg at month 3 to 32 mmHg 
at month 7.37 This particular patient’s IOP was successfully 
managed with combination topical IOP-lowering medication. 
At 13 months, left and right eye IOP, 6 months after FA 
implantation, was 21 and 18 mmHg, respectively.
With regards to the value of a corticosteroid provocation 
test, Breusegem et al looked at the predictive value of topical 
dexamethasone for IOP elevation before intravitreal triamci-
nolone and reported a positive predictive value of 100% and 
a negative predictive value of 62%.43 Additionally, a family 
history of glaucoma is a significant risk factor for the develop-
ment of steroid-induced IOP elevation and other risk factors 
include high myopia, diabetes mellitus, and connective tissue 
diseases.44,45 Although it has been quite reassuring from real-
world case series of patients treated with the FA implant 
that an elevated IOP can often be managed successfully, the 
results of their corticosteroid provocation tests, their baseline 
optic disc and visual field status, and other risk factors should 
all be taken into account when deciding on whether to use an 
FA implant for their DME. A recent publication by an expert 
panel suggested a risk stratification algorithm for managing 
patients treated with the FA implant based on the presence 
of ocular hypertension and glaucoma at baseline and also the 
level of IOP reached during the follow-up.28
Other adverse events
Moisseiev et al described a case of an FA implant 
causing a visually disturbing “floater” in the visual 
axis of previously vitrectomized eye.46 This required 
neodymium:yttriumalumin umgarnet laser vitreolysis of a 
vitreous attachment to remove the implant from the visual 
axis, which led to a resolution of the patient’s symptoms. 
Migration of FA implants into the anterior chamber has been 
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reported in two eyes of patients with previous complicated 
cataract surgery and vitrectomy.47 However, the successful 
repositioning from the anterior chamber into the vitreous 
cavity, without damage or complications to the eye or the 
implant, has been reported using a 23-gauge flute needle.48 
A theoretical risk of retinal detachment following intravitreal 
injection of the FA implant has not been demonstrated in 
the peer-reviewed literature.
Current on-going real-world studies on 
the iluvien implant
The Iluvien Registry Safety Study is a European, multicenter, 
open label, registry study assessing the real-life tolerability 
of Iluvien.49 Interim data analysis was presented in May 2016 
with further analysis due to take place in 2017. The study 
involves 26 sites in the UK, 10 sites in Germany, and 1 in 
Portugal. Data were presented for 328 eyes (292 patients). 
The average period of follow-up in the interim analysis was 
281.9 days (range: 3–763 days). 81.6% of patients did not 
require initiation of IOP treatment post-FA implantation. 
However, 2 of the 328 eyes required IOP-lowering surgery. 
In this group of patients with an extended duration of DME 
and 98.8% of whom had received prior therapy including 
intravitreal anti-VEGF and laser, visual acuity report-
edly improved in 58% of patients at 6 months and 61% at 
12 months. The Medisoft® electronic auditing tool has been 
used in the UK to retrospectively review real-world IOP 
events in 290 eyes of 258 patients following the FA implant.50 
14.8% of patients required the initiation of IOP-lowering 
medication. In the overall group, 69.4% of eyes maintained 
or had an improvement in visual acuity from month 3 through 
to month 24.
The RESPOND study is a prospective, nonrandomized, 
multicenter, open-label Phase IV pilot study that has been 
conducted across four sites in Portugal.51 In this study, 
12 patients received Iluvien 190 μg intravitreal implant at 
the inclusion visit and were followed up for eight visits over 
12 months. Changes in BCVA, CRT, and adverse events, 
namely cataract and elevated IOP, were studied from baseline 
to month 12. The results of this study are due to be published 
in the near future.
Finally, another vendor sponsored retrospective study 
called the Iluvien Clinical Evidence in the United Kingdom 
study has completed data collection on .300 patients from 
12 hospitals in the UK (Yang, unpublished data, 2017). The 
profiles on prior therapies, baseline characteristics at the 
time of Iluvien therapy, and 12-month outcome in visual 
acuity and IOP are expected to be reported in 2017.
In the coming years, there are likely to be many publica-
tions on the real-world outcomes of the FA implant for DME. 
There is a real possibility that the same cohort of patients 
either in part or in whole may be the subjects of more than 
one publication. In contrast to subsequent publications on 
post hoc analyses from the same data set of a clinical trial 
where it is clear where the patient data came from, this is not 
the case in real-world studies where data can be collected 
multiple times from the same patient or patients for several 
publications. Due to the high potential for duplication of 
reporting of real-world data, data from multiple publications 
originating from the same institutions must be interpreted 
with caution.
Conclusion
Since the initial FAME trial reporting the efficacy of FA 
implant for DME, intravitreal anti-VEGF agents have 
become firmly established as the first-line therapeutic agents 
for DME. The FA implant has been approved by regulatory 
authorities in many countries for the treatment of chronic 
DME and the role of FA implant has been mainly reserved 
for those patients who have persistent or recurrent sight-
threatening edema despite multiple and frequent administra-
tions of anti-VEGF therapy. For this challenging category of 
patients, there is now a wealth of published evidence-based 
real-world studies to support the clinical utility of FA implant 
in achieving further resolution of edema and improving visual 
acuity outcomes, thereby potentially reducing the burden of 
frequent injections and hospital visits.
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